Dr Reddy's

Dr Reddy’s picks up portfolio and facility from rival for $259m

17-Feb-2020 By Ben Hargreaves

Wockhardt sells part of its domestic business to fund growth in international markets and to develop its biosimilar business.

Dr. Reddy’s taps contract manufacturer to access Chinese market

11-Nov-2019 By Nick Taylor

Dr. Reddy’s Laboratories moves products to Chinese contract manufacturer in push to access major emerging market.

Sanofi and Dr Reddy’s join the ranitidine recall

24-Oct-2019 By Ben Hargreaves

Both companies issue a voluntary recall of their ranitidine-based products due to the ongoing investigation into cancer-causing contamination.

Suboxone competition ramps up as Indivior and Mylan launch generics

25-Feb-2019 By Maggie Lynch

Indivior launches generic of its own Suboxone film in the US, one day after court decision allows rivals to market generic versions.

Hired and Retired: In with the new

22-Feb-2019 By Ben Hargreaves

A number of companies spent the early part of the year creating and then filling new positions, which has seen another big pharma company follow the trend of appointing a chief digital officer.

Indivior succeeds in putting Suboxone generic on hold again

13-Dec-2018 By Maggie Lynch

Indivior’s patent litigation with Dr. Reddy’s over Suboxone film continues after the company announced its preliminary injunction will stay in place.

Dr. Reddy’s Duvvada site issued Form 483 with 8 observations

01-Nov-2018 By Maggie Lynch

Dr. Reddy’s formulations and manufacturing facility in Duvvada, India, was issued a letter noting eight violations after an audit by the US FDA.

Dr. Reddy’s sells Tennessee antibiotic manufacturing site

08-Oct-2018 By Maggie Lynch

Dr. Reddy’s Laboratories antibiotic manufacturing site in Bristol, Tennessee, has been sold to Neopharma, along with all issued and outstanding membership interests and related assets.